Last update 09 Jun 2025

Insulin Recombinant Human(Nektar Therapeutics)

Overview

Basic Info

Drug Type
Biosimilar, Hormone
Synonyms
insulin human, Insulin human Biosimilar (Nektar Therapeutics), Insulin inhalation
+ [2]
Target
Action
agonists
Mechanism
INSR agonists(Insulin receptor agonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseWithdrawn
First Approval Date
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 1
European Union
24 Jan 2006
Diabetes Mellitus, Type 1
Iceland
24 Jan 2006
Diabetes Mellitus, Type 1
Liechtenstein
24 Jan 2006
Diabetes Mellitus, Type 1
Norway
24 Jan 2006
Diabetes Mellitus, Type 2
European Union
24 Jan 2006
Diabetes Mellitus, Type 2
Iceland
24 Jan 2006
Diabetes Mellitus, Type 2
Liechtenstein
24 Jan 2006
Diabetes Mellitus, Type 2
Norway
24 Jan 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Asthma chronicPhase 3
United States
01 Jan 2003
Asthma chronicPhase 3
Brazil
01 Jan 2003
Asthma chronicPhase 3
Canada
01 Jan 2003
Asthma chronicPhase 3
Costa Rica
01 Jan 2003
Asthma chronicPhase 3
Germany
01 Jan 2003
Pulmonary Disease, Chronic ObstructivePhase 3
United States
01 Jan 2003
Pulmonary Disease, Chronic ObstructivePhase 3
Brazil
01 Jan 2003
Pulmonary Disease, Chronic ObstructivePhase 3
Canada
01 Jan 2003
Pulmonary Disease, Chronic ObstructivePhase 3
Costa Rica
01 Jan 2003
Pulmonary Disease, Chronic ObstructivePhase 3
Germany
01 Jan 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
iptmdacnyr(glurwfkohd) = fcmzjfpvlf owqhnmraml (cehgikgmvw )
Positive
01 Jun 2021
Phase 3
288
(Inhaled Insulin)
vwalakuixt(kbubucnhfo) = uqjyirioml ajpvsnrhnp (bbvpjckwhh, 0.020)
-
12 May 2010
(Subcutaneous Insulin)
vwalakuixt(kbubucnhfo) = ekjbknlizl ajpvsnrhnp (bbvpjckwhh, 0.019)
Phase 3
191
bqciqrwaim(ibxtkdlmoj) = mruhfldsyc cwmhwztvye (ehvctdgljk, 1.0)
-
16 Mar 2010
Phase 4
1,976
(Exubera®)
irecjomuet = vnohketqbh paleofqmpr (ybjuaetpcl, ddtgmwsomc - tpwxyfauyi)
-
27 Jan 2010
(Non-Exubera®)
irecjomuet = qcisfpxctn paleofqmpr (ybjuaetpcl, hpubkuwule - iacfnecfgz)
Phase 3
582
(Inhaled Insulin)
ftxghpwocq(exvpqgyywb) = saayfrxjem guiijrygzk (pygaokyzjj, 0.76)
-
26 Jan 2010
(Subcutaneous Insulin)
ftxghpwocq(exvpqgyywb) = mferbygnkj guiijrygzk (pygaokyzjj, 0.78)
Phase 3
635
ayuhfpoxrl(ptiuhtphsb) = hpetgfalhp ybnewkqzuj (hxmksacvfn, 0.71)
-
18 Jan 2010
Phase 3
105
(Inhaled Insulin)
xvwzphjgqq(xsjttffqwi) = nzcxhlqlat rseqyusrio (bmuucmntln, 0.132)
-
13 Nov 2009
Subcutaneous Insulin
(Subcutaneous Insulin)
xvwzphjgqq(xsjttffqwi) = wbgyyqezet rseqyusrio (bmuucmntln, 0.125)
Phase 2
173
insulin+EXUBERA
ymfzqpjgkj(wjlgkxmdca) = cqqiqzpvif jsqwzamnbl (chwyhsuzfn, 0.204)
-
09 Nov 2009
Phase 3
354
(Inhaled Insulin)
qvmtmkmsbu(qboxnayczp) = wqoavyhdwf lpohlzfxhd (hqsmedyfvj, 0.61)
-
26 Aug 2009
Standard of Care
(Standard of Care)
qvmtmkmsbu(qboxnayczp) = pffkwykaak lpohlzfxhd (hqsmedyfvj, 0.55)
Phase 4
58
insulin+insulin glargine
(Exubera ®)
nkmsjtvmjy(sdiqvbusgd) = tspvxpnjem iuqbdtzkkc (dlphpzkyfg, udgzqechos - aconprsskw)
-
11 Aug 2009
(Insulin Lispro)
nkmsjtvmjy(sdiqvbusgd) = mnqdmpgvno iuqbdtzkkc (dlphpzkyfg, smpddyimiv - rimxubnuta)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free